A polymorphism in the interleukin-10 promoter affects the course of disease in patients with clear-cell renal carcinoma

Human Immunology

Volumn 70, Issue 1, 2009, Pages 60-64

  Romero, José María ^a   Sáenz López, Pablo ^a   Cózar, José Manuel ^b   Carretero, Rafael ^a   Canton, Julia ^a   Vazquez, Fernando ^b   Concha, Angel ^b   Tallada, Miguel ^b   Garrido, Federico ^a   Ruiz Cabello, Francisco ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

IL 10; Polymorphisms; Renal cell cancer

Indexed keywords

INTERLEUKIN 10;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER RISK; CANCER STAGING; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HUMAN; IMMUNE RESPONSE; INTERLEUKIN 10 GENE; KIDNEY CARCINOMA; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; TH1 CELL; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-10; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; YOUNG ADULT;

EID: 58149471231     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2008.10.020     Document Type: Article

References (33)

1. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 (2002) 860-867
2. Balkwill F., Charles K.A., and Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7 (2005) 211-217
3. Ben-Baruch A. The multifaceted roles of chemokines in malignancy. Cancer Metastasis Rev 25 (2006) 357-371
4. Lech-Maranda E., Baseggio L., Bienvenu J., Charlot C., Berger F., Rigal D., et al. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood 103 (2004) 3529-3534
5. Pestka S., Krause C.D., Sarkar D., Walter M.R., Shi Y., and Fisher P.B. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 22 (2004) 929-979
6. Mocellin S., Marincola F.M., and Young H.A. Interleukin-10 and the immune response against cancer: A counterpoint. J Leukoc Biol 78 (2005) 1043-1051
7. Eskdale J., Gallagher G., Verweij C.L., Keijsers V., Westendorp R.G., and Huizinga T.W. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci U S A 95 (1998) 9465-9470
8. Kroeger K.M., Carville K.S., and Abraham L.J. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol 34 (1997) 391-399
9. Ueda H., Howson J.M., Esposito L., Heward J., Snook H., Chamberlain G., et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423 (2003) 506-511
10. Turner D.M., Williams D.M., Sankaran D., Lazarus M., Sinnott P.J., and Hutchinson I.V. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 24 (1997) 1-8
11. Suarez A., Castro P., Alonso R., Mozo L., and Gutierrez C. Interindividual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphisms. Transplantation 75 (2003) 711-717
12. Howell W.M., and Rose-Zerilli M.J. Interleukin-10 polymorphisms, cancer susceptibility and prognosis. Fam Cancer 5 (2006) 143-149
13. Cozar J.M., Romero J.M., Aptsiauri N., Vazquez F., Vilchez J.R., Tallada M., et al. High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. Hum Immunol 68 (2007) 698-704
14. Havranek E., Howell W.M., Fussell H.M., Whelan J.A., Whelan M.A., and Pandha H.S. An interleukin-10 promoter polymorphism may influence tumor development in renal cell carcinoma. J Urol 173 (2005) 709-712
15. Lam J.S., Shvarts O., Leppert J.T., Pantuck A.J., Figlin R.A., and Belldegrun A.S. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol 174 (2005) 466-472 discussion 472; quiz 801
16. Sasieni P.D. From genotypes to genes: Doubling the sample size. Biometrics 53 (1997) 1253-1261
17. Alonso R., Suarez A., Castro P., Lacave A.J., and Gutierrez C. Influence of interleukin-10 genetic polymorphism on survival rates in melanoma patients with advanced disease. Melanoma Res 15 (2005) 53-60
18. Lim S., Crawley E., Woo P., and Barnes P.J. Haplotype associated with low interleukin-10 production in patients with severe asthma. Lancet 352 (1998) 113
19. Koss K., Satsangi J., Fanning G.C., Welsh K.I., and Jewell D.P. Cytokine (TNF alpha, LT alpha and IL-10) polymorphisms in inflammatory bowel diseases and normal controls: Differential effects on production and allele frequencies. Genes Immun 1 (2000) 185-190
20. Rueda B., Roibas B., Martin J., and Gonzalez-Gay M.A. Influence of interleukin 10 promoter polymorphisms in susceptibility to giant cell arteritis in Northwestern Spain. J Rheumatol 34 (2007) 1535-1539
21. Seifart C., Plagens A., Dempfle A., Clostermann U., Vogelmeier C., von Wichert P., et al. TNF-alpha, TNF-beta, IL-6, and IL-10 polymorphisms in patients with lung cancer. Dis Markers 21 (2005) 157-165
22. Vairaktaris E., Yapijakis C., Serefoglou Z., Derka S., Vassiliou S., Nkenke E., et al. The interleukin-10 (-1082A/G) polymorphism is strongly associated with increased risk for oral squamous cell carcinoma. Anticancer Res 28 (2008) 309-314
23. Howell W.M., Turner S.J., Bateman A.C., and Theaker J.M. IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun 2 (2001) 25-31
24. McCarron S.L., Edwards S., Evans P.R., Gibbs R., Dearnaley D.P., Dowe A., et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 62 (2002) 3369-3372
25. Zheng L.M., Ojcius D.M., Garaud F., Roth C., Maxwell E., Li Z., et al. Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med 184 (1996) 579-584
26. Kundu N., Beaty T.L., Jackson M.J., and Fulton A.M. Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer. J Natl Cancer Inst 88 (1996) 536-541
27. Kaufman H.L., Rao J.B., Irvine K.R., Bronte V., Rosenberg S.A., and Restifo N.P. Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model. J Immunother 22 (1999) 489-496
28. Huang S., Ullrich S.E., and Bar-Eli M. Regulation of tumor growth and metastasis by interleukin-10: The melanoma experience. J Interferon Cytokine Res 19 (1999) 697-703
29. Lin W.W., and Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117 (2007) 1175-1183
30. Polverini P.J., and Leibovich S.J. Induction of neovascularization and nonlymphoid mesenchymal cell proliferation by macrophage cell lines. J Leukoc Biol 37 (1985) 279-288
31. Lin E.Y., Nguyen A.V., Russell R.G., and Pollard J.W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 193 (2001) 727-740
32. Di Carlo E., Coletti A., Modesti A., Giovarelli M., Forni G., and Musiani P. Local release of interleukin-10 by transfected mouse adenocarcinoma cells exhibits pro- and anti-inflammatory activity and results in a delayed tumor rejection. Eur Cytokine Netw 9 (1998) 61-68
33. Huang S., Xie K., Bucana C.D., Ullrich S.E., and Bar-Eli M. Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: Potential inhibition of angiogenesis. Clin Cancer Res 2 (1996) 1969-1979